Related Experiment Videos
[Beta receptor blockers in chronic heart failure]
Insights
Beta-blocker therapy benefits heart failure hemodynamics and clinical outcomes but does not reduce mortality. Ongoing trials investigate mechanisms and optimal beta-blocker selection for chronic heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic heart failure (CHF) management involves addressing hemodynamic and clinical parameters.
- Beta-blocker therapy has demonstrated positive effects on hemodynamics and clinical status in CHF patients with dilatated or ischemic cardiomyopathy.
Purpose:
- To elucidate the mechanisms underlying the hemodynamic improvements observed with beta-blocker therapy in chronic heart failure.
- To explore the potential impact of beta-blocker therapy on myocardial cellular function and catecholamine protection.
Summary:
- Controlled trials (MDC, CIBIS) confirm beta-blockers improve hemodynamics and clinical course in chronic heart failure, yet mortality benefits remain unproven.
- Postulated mechanisms include improved cellular calcium metabolism, enhanced myocardial contractility, and protection against catecholamine-induced cell necrosis.
- Ongoing trials aim to correlate improved hemodynamics and clinical course with reduced mortality and determine the most effective beta-blocker agents.
Impact:
- Provides insights into the complex mechanisms of beta-blocker action in heart failure.
- Highlights the need for further research to establish mortality benefits and guide optimal therapeutic choices.
- Informs clinical practice and future research directions in heart failure management.
Abstract:
Recently published data of the controlled MDC- and CIBIS-trials confirm the favorable effect of beta-blocker therapy on the hemodynamics and clinical course of patients with chronic heart failure due to dilatated and/or ischemic cardiomyopathy. However, mortality remains unchanged. The mechanisms by which beta-blocker therapy improves hemodynamics in chronic heart failure are not known reliably. It is postulated that the negative chronotropic effect of beta-blockers improves the cellular calcium metabolism and thereby increases myocardial contractility. Further effects of beta-blockers are protection of myocardial cells from enhanced catecholamine concentrations. This prevents cell necrosis and economizes the use of cell energy. The reversion of down-regulation of beta-1-receptors in beta-blocker therapy is most probably only an epiphenomenon. Major randomized clinical trials are ongoing to investigate whether improved hemodynamics and clinical course are correlated with decreased mortality. It also still remains open which substance is most beneficial (e.g., selective beta-blockers, beta-blockers with additional vasodilatatory effect).